Colorectal Cancer Clinical Trials in Phoenix

Showing 101-120 of 241 trials

A Phase 1 Study Evaluating the Safety of TRK-950 in Patients With Advanced Solid Tumors

NCT02990481

1. To determine the maximum tolerated dose (MTD) and the dose limiting toxicities (DLTs) of TRK-950 as single agent 2. To establish the dose of TRK-950 recommended for future phase 2 studies

Locally Advanced or Metastatic Solid CarcinomasColon CancerCholangiocarcinoma

Toray Industries, Inc38 participantsStarted Mar 2017

Phoenix, Arizona, United States • Scottsdale, Arizona, United States • Lyon, France

RECRUITINGPhase 2< 1 mile

Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients

NCT04291105

This is a Phase 2 study designed to determine the preliminary anti-tumor activity and confirm the safety of VV1 in combination with cemiplimab. The study will enroll patients with three distinct separate tumor cohorts. The cancers types are colorectal, head and neck carcinoma, and melanoma that are progressing on CPI treatment.

MelanomaHead and Neck Squamous Cell CarcinomaColo-rectal Cancer

Vyriad, Inc.87 participantsStarted Apr 2020

Phoenix, Arizona, United States • Durate, California, United States • Los Angeles, California, United States +24 more locations

A Phase 1 Study Evaluating the Safety of TRK-950 in Patients With Advanced Solid Tumors

Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients

Colorectal Cancer Trials in Other Cities

Study of Onvansertib in Combination With FOLFIRI and Bevacizumab Versus FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Participants With a Kirsten Rat Sarcoma Virus Gene (KRAS) or Neuroblastoma-RAS (NRAS) Mutation

Oral AMXT 1501 Dicaprate in Combination With IV DFMO

Capecitabine and Bevacizumab With or Without Atezolizumab in Treating Patients With Refractory Metastatic Colorectal Cancer

Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors

A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)

Expanded Access Study of TAS-102 in Patients With Metastatic Colorectal Cancer

Efficacy and Safety Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Adults With Selected Advanced/Metastatic Solid Tumors (MK-7123-034)

Binimetinib and Palbociclib or TAS-102 in Treating Patients With KRAS and NRAS Mutant Metastatic or Unresectable Colorectal Cancer

A Bioequivalence Study Between the Proposed and Current Talazoparib Capsule Formulation and Food Effect Study for the Proposed Talazoparib Capsule Formulation in Participants With Advanced Solid Tumors

Tucatinib Combined with Trastuzumab and TAS-102 for the Treatment of HER2 Positive Metastatic Colorectal Cancer in Molecularly Selected Patients, 3T Study

A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies

Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies

Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers

TT-10 (PORT-6) and TT-4 (PORT-7) as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors

Study of NIS793 and Other Novel Investigational Combinations With SOC Anti-cancer Therapy for the 2L Treatment of mCRC

LYT-200 Alone and in Combination With Chemotherapy or Tislelizumab in Patients With Locally Advanced or Metastatic Solid Tumors

ME-344 and Bevacizumab in Previously Treated Metastatic Colorectal Cancer

Selumetinib and Cyclosporine in Treating Patients With Advanced Solid Tumors or Advanced or Metastatic Colorectal Cancer

Other Conditions in Phoenix